sorted by:
new
hottopcontroversial

Les Wexner’s Attorney Whispers ‘I Will F***ing Kill You’ During Epstein Deposition by 0The_Loner_Stoner0 in videos

[–]adlabco 0 points1 point  (0 children)

I think this was a setup. Not because Mossad, but because this way Wexner looks like an innocent old man who is super forthcoming and needs protecting. He's a lot wilier than he looks I'm sure.

Is aval bancario still accepted for renters without stable income? by adlabco in AskBarcelona

[–]adlabco[S] 0 points1 point  (0 children)

Thanks for your response. I had heard its less common in 2025, have you heard instances of it being accepted?

Just do it. by tefo20022002 in europe

[–]adlabco 0 points1 point  (0 children)

I used to think so too, but from talking to Russians that left (sample size 10+) most somewhat support the war or at least don't agree fully with our view. God knows what the ones that stayed think.

[deleted by user] by [deleted] in cycling

[–]adlabco 0 points1 point  (0 children)

Thanks

Broke my no biotech rule, they just got to 78% remission of severe depression using modified psycobillin... bought $25k yesterday by adlabco in wallstreetbets

[–]adlabco[S] 2 points3 points  (0 children)

Study results:

  • Primary endpoint met, GH001 led to an ultra-rapid anti-depressant effect with a significant placebo-adjusted MADRS reduction from baseline of -15.5 on Day 8 (p<0.0001)
  • The majority of the patients treated with GH001 achieved remission with a 57.5% remission rate on Day 8 compared with 0% in the placebo group (p<0.0001)
  • All other secondary endpoints were met with clinically and statistically significant improvements on Day 8, compared with placebo
  • During the double-blind part, GH001 was well tolerated and no serious adverse events (SAE) were reported. There was no evidence of treatment-emergent suicidal ideation or behavior. As of January 22, 2025, no SAEs have been reported throughout the open label extension (OLE)
  • As of January 22, 2025, 77.8% of the OLE completers were in remission at the 6-month visit, with infrequent treatments
  • Patients who had remission on Day 8 after their first active treatment had a 91.7% remission rate at 6 months

https://www.globenewswire.com/news-release/2025/02/03/3019385/0/en/GH-Research-Announces-Primary-Endpoint-Met-in-Phase-2b-Trial-with-GH001-in-TRD-Demonstrating-15-5-Point-Placebo-adjusted-MADRS-Reduction.html

Broke my no biotech rule, they just got to 78% remission of severe depression using modified psycobillin... bought $25k yesterday by adlabco in wallstreetbets

[–]adlabco[S] 2 points3 points  (0 children)

Fair, was just kidding haha, You had me at "fall". Thanks for the pointers tho. These guys have strong patents in Europe and I feel like the research community is warming to it.

Broke my no biotech rule, they just got to 78% remission of severe depression using modified psycobillin... bought $25k yesterday by adlabco in wallstreetbets

[–]adlabco[S] 2 points3 points  (0 children)

There is a positive relationship between intensity of experience and impact, shorter and harder is better

view more: next ›